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| INTRODUC TI ON
Esophageal squamous cell carcinoma is one of the most common and lethal gastrointestinal malignancies worldwide. 1, 2 Despite multimodal treatments, such as radical surgery, chemotherapy, and radiotherapy, the 5-year survival rate of patients with ESCC remains extremely low due to its highly invasive and metastatic nature. 3, 4 The pathophysiology of ESCC is not entirely understood; thus, further research into the discovery and development of effective biomarkers for ESCC diagnosis, prognosis, and treatment is warranted.
The SEREX is an effective screening method for identifying serum Ab-type tumor markers. 5 We have previously undertaken large-scale SEREX screenings where numerous candidates for ESCC SEREX antigens were identified and potential novel diagnostic markers for digestive organ cancers were discovered. [6] [7] [8] [9] [10] [11] [12] In the majority of colorectal cancers, c-myc is overexpressed and required for tumor maintenance. 13, 14 The FUSE is a sequence required for the proper expression of the human c-myc gene. It is located 1.5 kb upstream of the c-myc promoter P1 and binds FUBP1, a transcription factor that stimulates c-myc expression in a FUSEdependent manner. 15, 16 The FUBP1 regulates the proliferation and migration of cells and is overexpressed in hepatocellular carcinoma. [17] [18] [19] Yeast 2-hybrid analysis revealed that FUBP1 binds to a protein that has transcriptional inhibitory activity, termed FIR, and FIR was found to engage the TFIIH/p89/XPB helicase and repress c-myc transcription.
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Apoptosis is induced by FIR through c-myc suppression; thus, it is a suitable target for anticancer therapy. 21, 22 FIRΔexon2, a splicing variant of FIR that lacks exon 2, failed to repress c-myc and inhibited FIR-induced apoptosis, suggesting that FIRΔexon2 is a dominant negative form of FIR in human cancers. 23 Alternatively, FIR is a splicing variant form of the poly(U)-binding-splicing factor, PUF60. 24, 25 Anti-PUF60 autoantibodies are reportedly detected in the sera of patients with autoimmune diseases such as dermatomyositis, Sjögren's syndrome, and idiopathic inflammatory myopathy. 26, 27 This suggests that the combination of anti-FIR Abs with other clinically available tumor markers, such as anti-p53 Abs, CEA, and CA19-9, could increase the specificity and accuracy of diagnosis. [28] [29] [30] [31] [32] The present study aimed to explore the presence and significance of anti-FIRΔexon2 Abs in the sera of patients with ESCC and to determine its use as a potential candidate marker.
| MATERIAL S AND ME THODS

| Clinical samples
The present study was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).
Sera of patients with ESCC (n = 95) were obtained from the Department of Frontier Surgery (Chiba University Hospital, Chiba, Japan). Sera of healthy donors (HDs) (n = 94) were obtained from the Higashi Funabashi Hospital, Funabashi City, Chiba, Japan. 
| Screening by expression cloning
Recombinant DNA studies were undertaken with permission from the Chiba University Graduate School of Medicine and were carried out in accordance with the rules of the Japanese government.
We used a λZAP II phage cDNA library prepared from the mRNA of Monoclonal phage cDNA clones were converted to pBluescript phagemids by excision in vivo using the ExAssist helper phage (Stratagene). Plasmid pBluescript containing cDNA was obtained from the E. coli SOLR strain after transformation by the phagemid.
The sequences of cDNA inserts were evaluated for homology with identified genes or proteins within the public sequence database (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
| Expression and purification of antigen proteins
The expression plasmids of GST-fused proteins were constructed by recombining the cDNA sequences into pGEX-4T-3 (GE Healthcare
Life Sciences, Pittsburgh, PA, USA). The inserted DNA fragments were ligated into pGEX-4T-3 using Ligation Convenience Kits (Nippon Gene). Ligation mixtures were used for transforming ECOS-competent E. coli BL21 (DE3) (Nippon Gene), and appropriate recombinants were confirmed by DNA sequencing as well as protein expression analyses. Treating the transformed E. coli with 0.1 mmol/L IPTG for 3 hours induced the expression of the GST-fusion proteins. The GST-fused recombinant proteins were purified by glutathione sepharose column chromatography in accordance with the manufacturer's instructions (GE Healthcare Life Sciences) and dialyzed against PBS as described in previous studies.
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| Amplified luminescence proximity homogeneous assay
Amplified luminescence proximity homogeneous assay (PerkinElmer Inc., Waltham, MA, USA) was carried out using 384-well microtiter plates (white opaque OptiPlate; PerkinElmer) containing 2.5 μL of 1:100-diluted sera and 2.5 μL GST or GST-fusion proteins (10 μg/mL)
in AlphaLISA buffer (25 mmol/L HEPES, pH 7.4, 0.1% casein, 0.5%
Triton X-100, 1 mg/mL dextran-500, and 0.05% Proclin-300). The reaction mixture was incubated at room temperature for 6-8 hours.
Next, anti-human IgG-conjugated acceptor beads (2.5 μL of 40 μg/ mL) and glutathione-conjugated donor beads (2.5 μL of 40 μg/mL) were added and incubated further for 7-21 days at room temperature in the dark. The chemical emission was read on an EnSpire
Alpha microplate reader (PerkinElmer) as previously described. [38] [39] [40] [41] [42] [43] Selective reactions were calculated by subtracting Alpha values of GST control from the values of GST-fusion proteins.
| Statistical analyses
All statistical analyses were undertaken using GraphPad Prism 7
(GraphPad Software, San Diego, CA, USA) and R 3. The combined ROC analysis was undertaken by adding each Z score.
To compare the significant differences among the single or combined ROCs, AUCs were calculated and examined by DeLong tests. 46 and cilia and flagella-associated protein 70 (CFAP70) (Accession No.
NM_145170.3)
. 58 Recombinant proteins were expressed in E. coli as GST-fusion proteins and were purified by affinity-chromatography using glutathione sepharose column (Table S1 ). 
| Higher levels of autoantibodies were detected in the sera of ESCC patients than that of healthy donors
The levels of serum autoantibodies were analyzed by AlphaLISA using the sera of HDs (Table S2) Abs (12/95, 13%) ( Table 1) . Clinical features of patients with ESCC are listed in Table 2 .
| Anti-FIRΔexon2 Ab is an independent marker of ESCC
Spearman's rank correlation analysis was used for exploring whether a correlation exists between FIRΔexon2, KARS, SNX15, SOHLH1,
TA B L E 1 Percentage of Ab-positive cases on AlphaLISA 
Female ( 
| Values of AUCs were increased in the combined ROC analysis compared to the individual ROC analysis
Receiver operating characteristic curve analysis was carried out for evaluating the ability of these candidate markers for detect- Among the Abs combined with the both p53 and CEA Abs, F I G U R E 2 Correlation coefficients between candidate markers and clinically used tumor markers for detection of ESCC patients. The correlation (Corr) between the groups was assessed using Spearman's rank correlation coefficient. The lower triangular matrix shows the pairwise scatter plots between variables, whereas the upper triangular matrix shows Spearman's rank correlation coefficients among each paired measurement
FIRΔexon2 Abs showed an AUC of greater than 0.750 in the sera of patients with ESCC. There were no Abs with an AUC larger than 0.750, however, the AUC values were increased in the combined ROC analysis compared to the individual ROC analysis ( Figure 4D ).
The highest AUC values were obtained for FIRΔexon2 + p53 Abs compared to all AUC values of ESCC.
The AUC values obtained for cancer classified as early or advanced stage are shown in Figure 5 . 
| D ISCUSS I ON
In the present study, we identified potential novel diagnostic markers for ESCC using SEREX screening. The combined ROC analysis of candidate Abs with anti-p53
Abs and CEA showed increased AUC values in the sera of patients with ESCC. Specifically, the combination of anti-p53 and
FIRΔexon2
Abs was shown to improve the diagnostic efficiency, thus aiding in the early detection of ESCC ( Figure 4 and Table 2 ).
Furthermore, the significance of ROCs among single or combined markers was examined through comparing the AUC by DeLong tests. 46, 49 In all stages of ESCCs, FIRΔexon2 Abs + p53 Abs or FIRΔexon2 Abs + CEA or FIRΔexon2 Abs + CEA + p53 Abs were significantly higher than that of CEA alone (Table S3 , middle column). Similarly, there was significance in early or advanced stages of ESCCs (Table S4) . Therefore, FIRΔexon2 Abs with anti-p53
Abs or CEA improves the specificity and sensitivity for screening
ESCCs. Further prospective multi-institutional studies comparing the sensitivity and specificity of this combinational detection approach will be required. 28 Amplified luminescence proximity homogeneous assay is an excellent method for measuring Ab levels compared with ELISA because of its low variation, stable background, and high specificity. It does not involve plate-washing steps; however, it involves mixing antigens with Abs in sera followed by the addition of donor and acceptor beads. For instance, Figure 1 showed highly reproducible results, including distributions, P values, and positive rates despite using different sets of sera from healthy donors and patients. AlphaLISA is a novel, recently developed method. After examining suitable AlphaLISA conditions in this study, we concluded 38 Prior to development, highly malignant tumors can induce necrosis, leading to the exposure of intracellular antigenic proteins to plasma. Therefore, using combinational Ab detection approaches could allow for the precise early detection of tumors. 28 In this study, we explored and examined 5 SEREX antigen markers for improved efficiency in diagnosing ESCC. To the best of our knowledge, our study is the first to suggest that FIRΔexon2, KARS, SNX15, SOHLH1, and CFAP70 Abs are candidate markers for ESCC and offer promise for the future selection of potential diagnostic markers.
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